Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources

    Research output: Contribution to journalReviewResearchpeer-review

  2. Drug-drug interactions between vitamin K antagonists and statins: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Use of prescription drugs in the older adult population-a nationwide pharmacoepidemiological study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Thromboembolic and bleeding complications following primary total knee arthroplasty: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Research output: Contribution to journalReviewResearchpeer-review

  4. Anvendt klinisk farmakologi

    Research output: Book/ReportBookpeer-review

  5. Cardiovascular risk management: A nationwide register-based study of patterns and secular changes of discontinuation prior to death

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

View graph of relations

PURPOSE: A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).

METHODS: We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation.

RESULTS: The infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.

CONCLUSION: We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.

Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
Volume76
Issue number1
Pages (from-to)35-40
Number of pages6
ISSN0031-6970
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • Anti-TNF drugs, Biological drugs, Biosimilars, Non-medical shift, Pharmacoeconomics

ID: 58296606